Pharma | Med Herald

editorialJune 9, 2026

0

Johnson & Johnson to buy Firefly Bio for $1 billion to strengthen cancer pipeline

The acquisition brings Firefly Bio’s proprietary Firelink™ degrader antibody conjugate platform into Johnson & Johnson’s oncology portfolio, expanding its focus…

editorialJune 9, 2026

0

Steroid scheduling change cuts early deaths in children with leukaemia, Indian trial finds

A simple change in the way steroids are given during treatment for childhood leukaemia could significantly reduce early treatment-related deaths…

editorialJune 8, 2026

0

India’s pharma industry can double in five years : Piyush Goyal

At a pharmaceutical industry event in New Delhi, the Commerce and Industry Minister said India is shifting towards innovation-driven drug…

editorialJune 8, 2026

0

Roche, Nurix join hands to develop new drug for blood cancers and immune disorders

Roche partners with Nurix to advance BTK degrader for blood cancers and immune disorders Bexobrutideg is set to enter Phase…

editorialJune 4, 2026

1

Nipocalimab cuts lupus disease activity in Phase 2 trial

Late-breaking data presented at EULAR 2026 showed sustained reductions in systemic lupus erythematosus disease activity through 52 weeks, with the…

editorialJune 3, 2026

0

Nipocalimab shows stronger responses in Sjögren’s disease patients with high autoantibody levels

New Phase 2 analyses presented by Johnson & Johnson suggest that adults with moderate-to-severe Sjögren’s disease and elevated disease-driving autoantibodies…

editorialJune 1, 2026

0

Serum Institute to manufacture Oxford’s Ebola vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI) has moved to accelerate the development of three investigational vaccines against Bundibugyo ebolavirus,…